Join
Live feed
·
PRReleasevia Quantisnow
CG Oncology Inc. logo

CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting

ByQuantisnow·Wall Street's wire, on your screen.
CGON· CG Oncology Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CGON (CG Oncology Inc.) and more on Quantisnow.